- Home
- USA vs VRDN Comparison
USA vs VRDN Comparison
Compare USA & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USA
- VRDN
- Stock Information
- Founded
- USA 1986
- VRDN 2006
- Country
- USA United States
- VRDN United States
- Employees
- USA N/A
- VRDN N/A
- Industry
- USA Finance Companies
- VRDN Medical Specialities
- Sector
- USA Finance
- VRDN Health Care
- Exchange
- USA Nasdaq
- VRDN Nasdaq
- Market Cap
- USA 1.9B
- VRDN 1.6B
- IPO Year
- USA N/A
- VRDN N/A
- Fundamental
- Price
- USA $6.55
- VRDN $13.48
- Analyst Decision
- USA
- VRDN Buy
- Analyst Count
- USA 0
- VRDN 12
- Target Price
- USA N/A
- VRDN $36.44
- AVG Volume (30 Days)
- USA 880.5K
- VRDN 766.3K
- Earning Date
- USA 01-01-0001
- VRDN 05-07-2025
- Dividend Yield
- USA 9.66%
- VRDN N/A
- EPS Growth
- USA N/A
- VRDN N/A
- EPS
- USA N/A
- VRDN N/A
- Revenue
- USA N/A
- VRDN $302,000.00
- Revenue This Year
- USA N/A
- VRDN N/A
- Revenue Next Year
- USA N/A
- VRDN $17,629.40
- P/E Ratio
- USA N/A
- VRDN N/A
- Revenue Growth
- USA N/A
- VRDN N/A
- 52 Week Low
- USA $5.62
- VRDN $11.40
- 52 Week High
- USA $7.09
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- USA 38.83
- VRDN 32.50
- Support Level
- USA $6.61
- VRDN $14.03
- Resistance Level
- USA $6.77
- VRDN $15.91
- Average True Range (ATR)
- USA 0.11
- VRDN 0.67
- MACD
- USA 0.01
- VRDN -0.10
- Stochastic Oscillator
- USA 45.00
- VRDN 6.51
About USA Liberty All-Star Equity Fund
Liberty All Star Equity Fund is a closed-end funds and open-end multi-managed fund. Its objective is to provide a high level of current income and long-term capital appreciation through investing primarily in a diversified portfolio of equity securities. The fund invests in various sectors, including financials, information technology, healthcare, consumer discretionary, consumer staples, industrials, energy, materials, real estate, utilities, telecommunication and other services.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.